HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Francesco Novelli Selected Research

Phosphopyruvate Hydratase (Enolase)

9/2015Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation.
5/2015Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
7/2013Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.
5/2013Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
4/2013Quartz crystal microbalance with dissipation (QCM-D) as tool to exploit antigen-antibody interactions in pancreatic ductal adenocarcinomadetection.
1/2013Three are better than one: plasminogen receptors as cancer theranostic targets.
4/2011α-Enolase: a promising therapeutic and diagnostic tumor target.
1/2011Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
6/2010Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells.
8/2009An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Francesco Novelli Research Topics

Disease

14Neoplasms (Cancer)
01/2015 - 01/2002
11Pancreatic Neoplasms (Pancreatic Cancer)
09/2015 - 08/2009
7Adenocarcinoma
05/2013 - 08/2009
4Anoxia (Hypoxia)
03/2015 - 12/2008
3Neoplasm Metastasis (Metastasis)
05/2015 - 01/2013
2Multiple Sclerosis
02/2012 - 05/2009
2Ectodermal Dysplasia (Aplasia Cutis Congenita)
04/2006 - 10/2003
2Infection
10/2004 - 06/2004
1Necrosis
02/2016
1Ischemia
03/2015
1Reperfusion Injury
03/2015
1Medulloblastoma
01/2015
1Psoriasis (Pustulosis Palmaris et Plantaris)
12/2014
1Neurodegenerative Diseases (Neurodegenerative Disease)
04/2014
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
12/2013
1Carcinoma (Carcinomatosis)
05/2013
1Prostatic Neoplasms (Prostate Cancer)
12/2010
1Substance-Related Disorders (Drug Abuse)
12/2010
1Dehydration (Water Stress)
06/2010
1Inflammation
08/2008
1Chronic Pancreatitis
10/2007
1Incontinentia Pigmenti (Bloch Sulzberger Syndrome)
04/2006
1Asthma (Bronchial Asthma)
08/2004

Drug/Important Bio-Agent (IBA)

10Phosphopyruvate Hydratase (Enolase)IBA
09/2015 - 08/2009
6Proteins (Proteins, Gene)IBA
03/2015 - 10/2007
5AntigensIBA
07/2013 - 10/2007
3AutoantibodiesIBA
09/2015 - 01/2011
3ProteomeIBA
03/2015 - 04/2011
2PlasminogenIBA
05/2015 - 01/2013
2Pyruvate KinaseIBA
03/2015 - 05/2013
2DNA (Deoxyribonucleic Acid)IBA
06/2014 - 05/2013
2Immunoglobulin G (IgG)IBA
05/2013 - 10/2007
2AntibodiesIBA
05/2013 - 10/2007
2OxygenIBA
04/2013 - 07/2012
1Transforming Growth Factors (Transforming Growth Factor)IBA
02/2016
1HLA-DR8IBA
09/2015
1Serine Proteases (Serine Protease)IBA
05/2015
1Complementary DNA (cDNA)IBA
05/2015
1FibrinolysinFDA Link
05/2015
1ArginaseIBA
03/2015
1Carrier Proteins (Binding Protein)IBA
01/2015
1IronIBA
01/2015
1interleukin-22 (IL-22)IBA
12/2014
1MHC class II transactivator proteinIBA
10/2014
1InterleukinsIBA
06/2014
1PerforinIBA
06/2014
1DNA-Binding Proteins (DNA Binding Protein)IBA
04/2014
1Acute-Phase Proteins (Acute-Phase Protein)IBA
12/2013
1HemopexinIBA
12/2013
1Complement System Proteins (Complement)IBA
05/2013
1PeptidesIBA
04/2013
1Pattern Recognition ReceptorsIBA
04/2013
1ezrinIBA
01/2013
1Keratin-8 (Keratin 8)IBA
01/2013
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
07/2012
1Lactic AcidFDA LinkGeneric
07/2012
1Pyruvic Acid (Pyruvate)IBA
07/2012
1Peptide Hydrolases (Proteases)IBA
06/2012
1Epidermal Growth Factor Receptor (EGF Receptor)IBA
06/2012
1erlotinib (CP 358,774)FDA Link
06/2012
1gemcitabineFDA Link
06/2012
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2012
1TransferasesIBA
06/2012
1Glutamine (L-Glutamine)FDA Link
02/2012
1Messenger RNA (mRNA)IBA
02/2012
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2012
1Cell Surface ReceptorsIBA
03/2011
1Biological Markers (Surrogate Marker)IBA
12/2010
1PhosphoenolpyruvateIBA
06/2010
12-phosphoglycerate (glycerate 2-phosphate)IBA
06/2010
1Interferon-betaIBA
05/2009
1Growth Factor ReceptorsIBA
08/2008
1Insulin (Novolin)FDA Link
03/2007
1NF-kappa B (NF-kB)IBA
04/2006
1Interleukin-12 (IL 12)IBA
10/2004
1Interferon-gamma (Interferon, gamma)IBA
08/2004
1Anti-Bacterial Agents (Antibiotics)IBA
06/2004
1Caspase 8 (Caspase-8)IBA
01/2004
1I-kappa B KinaseIBA
10/2003
1NF-kappaB inhibitor alphaIBA
10/2003
1Death Domain ReceptorsIBA
01/2002
1LigandsIBA
01/2002

Therapy/Procedure

1Immunotherapy
10/2014
1Heterologous Transplantation (Xenotransplantation)
05/2013
1Pancreaticoduodenectomy
05/2013